Mergers & acquisitions
One day after it was revealed Takeda is moving its U.S. headquarters from Illinois to Boston ahead of the completion of the Shire Plc acquisition, the Japanese company is reportedly considering the sale of Shire’s eye-care business in order to cut some debt incurred from funding the $62 billion deal.
Takeda Pharmaceuticals will shutter its Deerfield, Ill. U.S. headquarters and move the operations to Boston as the company consolidates its operations following the $62 billion acquisition of Shire.
The opposition to Takeda Pharmaceutical acquiring Shire has taken on another dimension with a prominent member of the family that created the Japanese pharmaceutical company speaking publicly against the deal.
Amedica Corporation today announced that it has entered into an asset purchase agreement with CTL Medical, whereby CTL Medical will acquire all of Amedica’s commercial spine business for total consideration of up to $10 million.
Penumbra, Inc. today announced it has closed on the acquisition of a controlling interest in its joint venture, MVI Health Inc.
Today Narasimhan and Novartis announced they were selling U.S. dermatology and generic drug assets, parts of its Sandoz division, to India’s Aurobindo Pharma for up to $1 billion. The deal includes approximately 300 products.
Touting that it is helping fight the opioid epidemic, Emergent BioSolutions is acquiring Adapt Pharma. Under the terms of the deal, Emergent will pay $635 million up front and up to $100 million in cash for various sales-based milestones through 2022.
Vantage Pharma published a report that reviewed the biopharma and medical technology trends for the year-to-date. Broadly speaking, for biotech companies, venture capital investment is up and mergers and acquisitions is down, while for the medical device company it’s the reverse.
Copenhagen, Denmark-based Novo Nordisk acquired Bristol, UK-based Ziylo in a deal that could exceed $800 million.
Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—mostly gains—at the six-month mark.
PRESS RELEASES